Wellcome Trust Sanger Institute Selects Geneservice to Provide Whole Genome Amplification
News Mar 28, 2006
Geneservice Ltd has announced that the Wellcome Trust Sanger Institute has chosen Geneservice to provide whole genome amplification for circa 25,000 samples from multiple studies including the Wellcome Trust Case Control Consortium (WTCCC), EPIC (obesity), MalariaGen, and the International 1q type 2 diabetes consortium.
Expanding the amount of DNA available will allow multiple future experiments on these samples that have been collected over many years.
Evaluation of suppliers, was based on a common set of samples tested post-amplification with the Affymetrix™ Genechip as well as Illumina Golden Gate and Infinium technologies.
The selection of Geneservice was based on a combination of responsiveness, performance, quality of service and value for money.
Tom Weaver, CEO of Geneservice commented, "I am delighted that we have been awarded this prestigious project against strong international competition. Working with world class scientific teams and being entrusted to amplify their samples is a tribute to the dedicated Geneservice team."
Panos Deloukas of the Wellcome Trust Sanger Institute added, "We looked for a provider to work closely with us to develop robust protocols for these important projects."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.